Incepta Pharmaceuticals Ltd: GLP-1 import refusal records
Has FDA refused imports of GLP-1 products from Incepta Pharmaceuticals Ltd?
Yes. FDA’s import refusal records list 5 refused shipment lines declared as made by Incepta Pharmaceuticals Ltd (Bangladesh) whose FDA product code names semaglutide, from Jun 26, 2024 to Feb 7, 2026. None of them carries a product code that FDA’s Import Alert 66-80 lists as a GLP-1 API or powder form.
- Spellings in FDA records
- Incepta Pharmaceuticals Ltd; INCEPTA PHARMACEUTICALS; INCEPTA PHARMACEUTICALS LTD
- Country
- Bangladesh
- City in FDA records
- Dhaka
- FEI numbers on the lines
- 3007306071, 3038731173, 3018092119
- Refused lines
- 5
- Lines with an Import Alert 66-80 API or powder code
- 0
- Drugs named in the product codes
- Semaglutide
- Refusal dates
- Jun 26, 2024 to Feb 7, 2026
The declared manufacturer is the firm named on the import entry. A refusal is FDA’s decision on one shipment line; it is not a finding about the firm’s other products.
Import Alert 66-80’s Green List (published Oct 9, 2026) prints a redaction in place of every firm name, so this index cannot say whether Incepta Pharmaceuticals Ltd is on it.
Refused shipment lines
| FDA refusal charges | Shipment ID | ||||
|---|---|---|---|---|---|
| Feb 7, 2026 | Bangladesh | 61PCP72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | 799-8328738-7/10002/1 |
| Sep 24, 2025 | Bangladesh | 61PCY72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | AEK-7364558-0/12/1 |
| May 2, 2025 | Bangladesh | 61PCY72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | AEK-8456378-0/11/1 |
| Oct 8, 2024 | Bangladesh | 61PCM72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | SCS-6288609-2/11/1 |
| Jun 26, 2024 | Bangladesh | 61PCY72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | SCS-4456039-3/11/1 |
FDA refusal charges on these lines
A line can carry several charges. Text is FDA’s charge statement, verbatim.
| UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | 5 |
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
Records last pulled Nov 15, 2026. Every entry links to the original public record.
5 lines from FDA files read Nov 15, 2026.